drug
Entia
Marketedupdated 3mo agoby Teva Pharmaceuticals USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval16 co-mentions · 8 sources
- drugXalox9 co-mentions · 9 sources
- drugOXALIPLATIN9 co-mentions · 9 sources
- tagOncology2 co-mentions · 1 sources
- drugFLUOROURACIL1 co-mentions · 1 sources
- drugEfudex1 co-mentions · 1 sources
- drugFAVLYXA1 co-mentions · 1 sources
- companyTehran University of Medical Sciences1 co-mentions · 1 sources
all catalysts(0)
nothing on the calendar yet
Trials studying Entia
- phase3Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
- phase2Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- phase2A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
- phase3A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- phase3Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- phase3A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
- phase2A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
- phase1A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
News(2)
- An ADC specialist sinks on safety concerns for blood cancer drugShares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”biopharma_dive · 2mo ago
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.onclive · 3mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that